title: Reversal of chronic rejection after treatment failure with FK506 and RS61443.
authors.forename: J P
authors.initials: JP
authors.lastname: Roberts
authors.forename: J R
authors.initials: JR
authors.lastname: Lake
authors.forename: M
authors.initials: M
authors.lastname: Hebert
authors.forename: B
authors.initials: B
authors.lastname: Nikolai
authors.forename: N L
authors.initials: NL
authors.lastname: Ascher
authors.forename: L D
authors.initials: LD
authors.lastname: Ferrell
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000601:surgery; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000150:complications / Q000601:surgery; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000150:complications / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D009173:Mycophenolic Acid; D016559:Tacrolimus